• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

Recent Advances in the Study of Tert-Butyl 1H-imidazol-2-ylcarbamate (CAS: 1339778-72-1) in Chemical Biology and Pharmaceutical Research

Tert-Butyl 1H-imidazol-2-ylcarbamate (CAS: 1339778-72-1) is a chemical compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its imidazole core and tert-butyl carbamate moiety, serves as a versatile intermediate in the synthesis of various biologically active molecules. Recent studies have explored its role in the development of novel therapeutic agents, particularly in the areas of oncology, infectious diseases, and neurological disorders. The unique structural features of this compound make it a valuable scaffold for designing inhibitors targeting specific enzymes and receptors.

One of the key areas of research involving Tert-Butyl 1H-imidazol-2-ylcarbamate is its application in the synthesis of kinase inhibitors. Kinases play a critical role in cellular signaling pathways, and their dysregulation is often associated with cancer and other diseases. Recent publications have highlighted the use of this compound as a building block for the development of selective kinase inhibitors with improved pharmacokinetic properties. For instance, a 2023 study demonstrated its utility in the synthesis of potent and selective inhibitors of the JAK-STAT pathway, which is implicated in inflammatory and autoimmune diseases. The study reported that derivatives of Tert-Butyl 1H-imidazol-2-ylcarbamate exhibited enhanced binding affinity and reduced off-target effects compared to earlier generations of inhibitors.

In addition to its role in kinase inhibitor development, Tert-Butyl 1H-imidazol-2-ylcarbamate has also been investigated for its potential in antimicrobial drug discovery. A recent study published in the Journal of Medicinal Chemistry (2024) explored the compound's efficacy against drug-resistant bacterial strains. The researchers synthesized a series of analogs and evaluated their antibacterial activity, finding that certain derivatives displayed potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant pathogens. The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, a mechanism distinct from that of conventional antibiotics.

Another promising avenue of research involves the use of Tert-Butyl 1H-imidazol-2-ylcarbamate in the development of neuroprotective agents. A 2023 study in ACS Chemical Neuroscience reported that derivatives of this compound exhibited significant neuroprotective effects in models of neurodegenerative diseases such as Alzheimer's and Parkinson's. The researchers identified that these derivatives could modulate key pathways involved in oxidative stress and neuroinflammation, suggesting their potential as therapeutic candidates for these debilitating conditions. The study also highlighted the compound's favorable blood-brain barrier permeability, a critical factor for CNS-targeted drugs.

Despite these promising findings, challenges remain in the optimization and clinical translation of Tert-Butyl 1H-imidazol-2-ylcarbamate-based therapeutics. Recent reviews have pointed out the need for further studies to address issues such as metabolic stability, toxicity profiles, and formulation strategies. However, the growing body of research underscores the compound's potential as a valuable tool in chemical biology and drug discovery. Future studies are expected to explore its applications in other therapeutic areas and to refine its structural features for enhanced efficacy and safety.

In conclusion, Tert-Butyl 1H-imidazol-2-ylcarbamate (CAS: 1339778-72-1) represents a promising scaffold in medicinal chemistry, with diverse applications ranging from kinase inhibition to antimicrobial and neuroprotective therapies. The latest research highlights its versatility and potential for addressing unmet medical needs, paving the way for further exploration and development in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)